---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-23-000083"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T12:30:23.565549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ligand Q3 adjusted EPS $1.02, revenue $32.9M; raises 2023 guidance; invests $75M+

## Summary
- Q3 total revenue $32.9M; ex-COVID revenue $26.9M vs $26.9M prior year. Net loss $0.74 GAAP per share.
- Adjusted net income $18.0M ($1.02 diluted EPS) vs $10.5M ($0.60) YoY; 2023 adjusted EPS guidance raised to $5.25-$5.40.
- Royalties $23.9M (+24% YoY) led by Kyprolis, Rylaze, Vaxneuvance, Filspari. Core Captisol $8.6M vs $3.6M.
- Invested over $75M in Q3/early Q4: $30M in Ovid soticlestat royalty, $20M for Tolerance/TZIELD royalty, $12.2M Novan purchase, $15M Primrose Bio.
- New $75M revolving credit facility with Citibank; cash & investments $190.5M at Sept 30. Revenue guidance raised to $126-$129M.

## SEC filing metadata
- accession: 0000886163-23-000083
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616323000083/0000886163-23-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616323000083/lgnd-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-23-000083
- JSON: https://secwatch.observer/filing/0000886163-23-000083.json
- Plain text: https://secwatch.observer/filing/0000886163-23-000083.txt

## Key facts
- Earnings Releases
  LIGAND PHARMACEUTICALS INC updated its three and nine months ended September 30, 2023 guidance (raised).
  - Period: three and nine months ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On November 8, 2023, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616323000083/0000886163-23-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.